An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia

키워드

참고문헌 (65)

1. Elvevåg B., "Cognitive impairment in schizophrenia is the core of the disorder", Crit Rev Neurobiol, 14, pp.1~21 (2000)
2. Barch DM., "Cognition in schizophrenia : core psychological and neural mechanisms", Trends Cogn Sci, 16, pp.27~34 (2012)
3. Llorca PM., "Partial compliance in schizophrenia and the impact on patient outcomes", Psychiatry Res, 161, pp.235~247 (2008)
4. Robinson DG., "Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder", Schizophr Res, 57, pp.209~219 (2002)
5. Green MF., "Cognitive impairment and functional outcome in schizophrenia and bipolar disorder", J Clin Psychiatry, 67(Suppl 9), pp.3~8 (2006)
6. Ibrahim HM., "Treating impaired cognition in schizophrenia", Curr Pharm Biotechnol, 13, pp.1587~1594 (2012)
7. Harvey PD., "Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment", Am J Psychiatry, 158, pp.176~184 (2001)
8. Meltzer HY., "The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia", Schizophr Bull, 25, pp.233~255 (1999)
9. Sumiyoshi T., "Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia", Front Behav Neurosci, 7, pp.140~ (2013)
10. Lieberman JA., "A randomized exploratory trial of an α-7 nicotinic receptor agonist(TC-5619)for cognitive enhancement in schizophrenia", Neuropsychopharmacology, 38, pp.968~975 (2013)
11. Shiina A., "A randomised, double-blind, placebocontrolled trial of tropisetron in patients with schizophrenia", Ann Gen Psychiatry, 9, pp.27~ (2010)
12. Niitsu T., "A randomized, double-blind, placebocontrolled trial of fluvoxamine in patients with schizophrenia : a preliminary study", J Clin Psychopharmacol, 32, pp.593~601 (2012)
13. Niitsu T., "Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases", Curr Pharm Des, 18, pp.875~883 (2012)
14. Huerta-Ramos E., "Effects of raloxifene on cognition in postmenopausal women with schizophrenia : a double-blind, randomized, placebo-controlled trial", Eur Neuropsychopharmacol, 24, pp.223~231 (2014)
15. Lane HY., "Add-on treatment of benzoate for schizophrenia : a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor", JAMA Psychiatry, 70, pp.1267~1275 (2013)
16. Keefe RS., "Clinical trials of potential cognitiveenhancing drugs in schizophrenia : what have we learned so far?", Schizophr Bull, 39, pp.417~435 (2013)
17. Do KQ., "Redox dysregulation and oxidative stress in schizophrenia : nutrigenetics as a challenge in psychiatric disease prevention", World Rev Nutr Diet, 101, pp.131~153 (2010)
18. Saruwatari J., "Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia", Neuropsychiatr Dis Treat, 9, pp.1683~1698 (2013)
19. Yao JK., "Antioxidants, redox signaling, and pathophysiology in schizophrenia : an integrative view", Antioxid Redox Signal, 15, pp.2011~2035 (2011)
20. Bitanihirwe BK., "Oxidative stress in schizophrenia : an integrated approach", Neurosci Biobehav Rev, 35, pp.878~893 (2011)
21. Zhang XY., "Plasma total antioxidant status and cognitive impairments in schizophrenia", Schizophr Res, 139, pp.66~72 (2012)
22. Wu JQ., "Cognition impairment in schizophrenia patients with tardive dyskinesia : association with plasma superoxide dismutase activity", Schizophr Res, 152, pp.210~216 (2014)
23. Zhang XY., "Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity : a case-control study", J Psychiatr Res, 47, pp.1049~1053 (2013)
24. Gubert C., "Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects", J Psychiatr Res, 47, pp.1396~1402 (2013)
25. Reddy R., "Antioxidant therapeutics for schizophrenia", Antioxid Redox Signal, 15, pp.2047~2055 (2011)
26. Berk M., "N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial", Biol Psychiatry, 64, pp.361~368 (2008)
27. Yao JK., "Oxidative damage and schizophrenia : an overview of the evidence and its therapeutic implications", CNS Drugs, 15, pp.287~310 (2001)
28. Zhang XY., "A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia", J Clin Psychiatry, 62, pp.878~883 (2001)
29. Emsley R., "Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia", Am J Psychiatry, 159, pp.1596~1598 (2002)
30. Mahadik SP., "Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 25, pp.463~493 (2001)
31. Peet M., "Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia", Schizophr Res, 49, pp.243~251 (2001)
32. Peet M., "A dose-ranging exploratory study of the effects of ethyleicosapentaenoate in patients with persistent schizophrenic symptoms", J Psychiatr Res, 36, pp.7~18 (2002)
33. Fenton WS., "A placebo-controlled trial of omega-3 fatty acid(ethyl eicosapentaenoic acid)supplementation for residual symptoms and cognitive impairment in schizophrenia", Am J Psychiatry, 158, pp.2071~2074 (2001)
34. Chengappa KN., "A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia", Schizophr Res, 142, pp.145~152 (2012)
35. Juge N., "Molecular basis for chemoprevention by sulforaphane : a comprehensive review", Cell Mol Life Sci, 64, pp.1105~1127 (2007)
36. pyrene-induced stomach tumors, "Proc Natl Acad Sci U S A", 2002, 7610~7615
37. Chen H., "Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine", Psychopharmacology(Berl), 222, pp.37~45 (2012)
38. Yumi Shirai, "Effects of the Antioxidant Sulforaphane on Hyperlocomotion and Prepulse Inhibition Deficits in Mice after Phencyclidine Administration", Clinical Psychopharmacology and Neuroscience, 10(2), pp.94~98 (2012), 대한정신약물학회[DOI]
39. Hashimoto K., "Brain-derived neurotrophic factor as a biomarker for mood disorders : an historical overview and future directions", Psychiatry Clin Neurosci, 64, pp.341~357 (2010)
40. Hashimoto K., "Sigma-1 receptor chaperone and brain-derived neurotrophic factor : emerging links between cardiovascular disease and depression", Prog Neurobiol, 100, pp.15~29 (2013)
41. American Psychiatric Association., "Diagnostic and statistical manual of mental disorders : DSM-IV-TR. 4th ed" (2000), American Psychiatric Press
42. Yoshida T., "Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia", PLoS One, 6, pp.e20469~ (2011)
43. Lim YY., "Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease : results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy(AIBL-ROCS)", Arch Clin Neuropsychol, 28, pp.320~330 (2013)
44. Kay SR., "The positive and negative syndrome scale(PANSS)for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
45. Busner J., "The clinical global impressions scale : applying a research tool in clinical practice", Psychiatry(Edgmont), 4, pp.28~37 (2007)
46. Kern RS., "The MATRICS Consensus Cognitive Battery, part 2 : co-norming and standardization", Am J Psychiatry, 165, pp.214~220 (2008)
47. Nuechterlein KH., "The MATRICS Consensus Cognitive Battery, part 1 : test selection, reliability, and validity", Am J Psychiatry, 165, pp.203~213 (2008)
48. Pietrzak RH., "Stability of cognitive impairment in chronic schizophrenia over brief and intermediate re-test intervals", Hum Psychopharmacol, 24, pp.113~121 (2009)
49. Maruff P., "Validity of the CogState brief battery : relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex", Arch Clin Neuropsychol, 24, pp.165~178 (2009)
50. Yoshida T., "Decreased serum levels of mature brain-derived neurotrophic factor(BDNF), but not its precursor proBDNF, in patients with major depressive disorder", PLoS One, 7, pp.e42676~ (2012)
51. Wild K., "Status of computerized cognitive testing in aging : a systematic review", Alzheimers Dement, 4, pp.428~437 (2008)
52. Fredrickson J., "Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies", Neuroepidemiology, 34, pp.65~75 (2010)
53. Ichimura S., "Assessment of cognitive function before and after surgery for posterior cranial fossa lesions using computerized and conventional tests", Neurol Med Chir(Tokyo), 50, pp.441~448 (2010)
54. Lim YY., "Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle(AIBL)study", J Clin Exp Neuropsychol, 34, pp.345~358 (2012)
55. Mas S., "Sulforaphane protects SK-N-SH cells against antipsychoticinduced oxidative stress", Fundam Clin Pharmacol, 26, pp.712~721 (2012)
56. Falleti MG., "Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals", J Clin Exp Neuropsychol, 28, pp.1095~1112 (2006)
57. Pietrzak RH., "A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia(MATRICS)Battery in assessing cognitive impairment in chronic schizophrenia", J Clin Exp Neuropsychol, 31, pp.848~859 (2009)
58. Darby DG., "Intraindividual cognitive decline using a brief computerized cognitive screening test", Alzheimers Dement, 8, pp.95~104 (2012)
59. Hammers D., "Reliability of repeated cognitive assessment of dementia using a brief computerized battery", Am J Alzheimers Dis Other Demen, 26, pp.326~333 (2011)
60. Cole WR., "Test-retest reliability of four computerized neurocognitive assessment tools in an active duty military population", Arch Clin Neuropsychol, 28, pp.732~742 (2013)
61. Murthy NV., "Computerized cognitive remediation training for schizophrenia : an open label, multi-site, multinational methodology study", Schizophr Res, 139, pp.87~91 (2012)
62. Green MJ., "Brain-derived neurotrophic factor levels in schizophrenia : a systematic review with meta-analysis", Mol Psychiatry, 16, pp.960~972 (2011)
63. Pandya CD., "BDNF-TrkB signaling and neuroprotection in schizophrenia", Asian J Psychiatr, 6, pp.22~28 (2013)
64. Carlino D., "Is altered BDNF biosynthesis a general feature in patients with cognitive dysfunctions?", Neuroscientist, 19, pp.345~353 (2013)
65. Milawaty Nurjono, "A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia", Clinical Psychopharmacology and Neuroscience, 10(2), pp.61~70 (2012), 대한정신약물학회[DOI]

관련 논문AI추천